Skip to content
value.today
Coronado Biosciences Inc. logo

Coronado Biosciences Inc.

Total raised
$52 M
5 rounds on record
Latest round
$26 M
May 2011
First round on record
Jul 2009
Today
Went public
See the company page

Coronado Biosciences Inc. is listed today as Fortress Biotech, Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Coronado Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2017$3 MPrivate placement after listing$2 to $10 million

Coronado Biosciences Inc.: Private sale, Mar 2017

Investors in this round

2 investors had bought by the notice of Apr 19, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$325,400
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • George K. Avgerinos · Executive Officer
  • Lindsay A. Rosenwald · Executive Officer, Director
  • Lucy S. Lu · Executive Officer
  • Dov K. Klein · Director
  • Eric K. Rowinsky · Director
  • J. Jay Lobell · Director
  • Jimmie S. Harvey, Jr. · Director
  • Malcolm S. Hoenlein · Director
  • Michael S. Weiss · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · broker-dealer National Securities Corporation (CRD 7569) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “In addition to the cash commission above, Issuer also issued warrants to purchase 87,946 shares of the Company's common stock at an exercise price of $3.70 per share.”
  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Lindsay A. Rosenwald, MD, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 19, 2017. Read the notice at the SEC.

debt, optionsSEC
May 2011$26 MNo. 5$10 to $50 million

Coronado Biosciences Inc.: Raise no. 5, May 2011

Investors in this round

344 investors had bought by the notice of Jul 5, 2011: 344 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $29 M offered; $3 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,580,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bobby W. Sandage · Executive Officer, Director
  • Dale W. Ritter · Executive Officer
  • Glenn L. Cooper · Executive Officer, Director
  • David J. Barrett · Director
  • Eric K. Rowinsky · Director
  • J. Jay Lobell · Director
  • Jimmie Jay Harvey · Director
  • Lindsay A. Rosenwald · Director
  • Michael W. Rogers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · New York, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “Includes aggregate amount receivable upon exercise of a warrant to purchase the Issuer's Common Stock and warrants to purchase the Issuer's Series C Preferred Stock (assuming no net exercise, where applicable). The warrants have not yet been exercised.”

Signed by Dale Ritter, Sr. VP. , Finance. Source: SEC Form D and 1 amendment, newest notice filed Jul 5, 2011. Read the notice at the SEC.

equity, optionsSEC
Jan 2011$14 MNo. 4$10 to $50 million

Coronado Biosciences Inc.: Raise no. 4, Jan 2011

Investors in this round

1 investor had bought by the notice of Jan 19, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elizabeth Moore · Executive Officer
  • Gary L. Gemignani · Executive Officer
  • Glenn L. Cooper · Executive Officer, Director
  • Peggy M. Wentworth · Executive Officer
  • Timothy M. Hillman · Executive Officer
  • Timothy M. Hofer · Executive Officer
  • Eric K. Rowinsky · Director
  • J. Jay Lobell · Director
  • Jimmie M. Harvey · Director
  • Lindsay A. Rosenwald · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents value of certain shares of the Issuer's preferred stock which were exchanged as consideration for the acquisition of certain assets.”

Signed by Gary Gemignani, Executive VP, COO & CFO. Source: SEC Form D, newest notice filed Jan 19, 2011. Read the notice at the SEC.

equitySEC
May 2010$4 MNo. 3$2 to $10 million

Coronado Biosciences Inc.: Raise no. 3, May 2010

Investors in this round

41 investors had bought by the notice of Jun 8, 2010: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $28 M offered; $24 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,499,999
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elizabeth J. Moore · Executive Officer
  • Gary L. Gemignani · Executive Officer
  • Linda J. Rogers · Executive Officer
  • Peggy M. Wentworth · Executive Officer
  • Raymond J. Tesi · Executive Officer, Director
  • Timothy M. Hofer · Executive Officer
  • Glenn L. Cooper · Director
  • J. Jay Lobell · Director
  • Jimmie M. Harvey · Director
  • Lindsay A. Rosenwald · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paramount BioCapital, Inc. (CRD 29795) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “Estimate represents maximum sales commission payable.”
  • On the amounts: “Includes amounts receivable upon exercise of certain warrants. The warrants have not yet been exercised.”

Signed by Timothy Hofer, Secretary. Source: SEC Form D, newest notice filed Jun 8, 2010. Read the notice at the SEC.

equity, optionsSEC
Apr 2010$7 MNo. 2$2 to $10 million

Coronado Biosciences Inc.: Raise no. 2, Apr 2010

Investors in this round

25 investors had bought by the notice of May 7, 2010: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $8 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elizabeth J. Moore · Executive Officer
  • Linda J. Rogers · Executive Officer
  • Peggy M. Wentworth · Executive Officer
  • Raymond J. Tesi · Executive Officer, Director
  • Stephen M. Pilatzke · Executive Officer
  • Timothy M. Hofer · Executive Officer
  • Glenn L. Cooper · Director
  • J. Jay Lobell · Director
  • Jimmie M. Harvey · Director
  • Lindsay A. Rosenwald · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paramount BioCapital, Inc. (CRD 29795) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Upon each closing, the Issuer will pay Paramount commissions equal to 10% of the gross proceeds received at such closing. The commissions paid above were not applied to the purchase of securities by one investor.”

Signed by Timothy Hofer, Secretary. Source: SEC Form D, newest notice filed May 7, 2010. Read the notice at the SEC.

equity, optionsSEC
Jul 2009$1 MNo. 1Under $2 million

Coronado Biosciences Inc.: Raise no. 1, Jul 2009

Investors in this round

16 investors had bought by the notice of Aug 4, 2009: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Coronado Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible Promissory Notes convertible into shares of Preferred Stock, Warrant to Purchase Common Stock and Common Stock issuable upon exercise of the Warrant.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$85,050
Finders' fees
none
Paid to its own people
$200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elizabeth Moore · Executive Officer
  • Linda Rogers · Executive Officer
  • Peggy Wentworth · Executive Officer
  • Raymond J. Tesi · Executive Officer, Director
  • Stephen Pilatzke · Executive Officer
  • Timothy M. Hofer · Executive Officer
  • Bertrand Liang · Director
  • J. Jay Lobell · Director
  • Jimmie Harvey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paramount BioCapital, Inc. (CRD 29795) · New York, NySold in all US states

Remarks in the notice

  • On fees: “Upon each closing, the Issuer will pay Paramount commissions equal to 7% of the gross proceeds received at such closing, up to $245,000. The commissions paid above were not applied to the purchase of securities by one investor.”
  • On the amounts: “Issuer may issue Convertible Promissory Notes in the principal amount of up to $3,500,000 and a Warrant to purchase Common Stock. The offering amount with respect to the Warrant is based on future values and can not be determined at this time.”
  • On the use of proceeds: “Certain proceeds of the offering will be used to pay employee wages owed to the individuals named in Item 3 above, and certain other employees of the Issuer who are related persons.”

Signed by Timothy Hofer, Secretary. Source: SEC Form D, newest notice filed Aug 4, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Fortress Biotech, Inc., its revenue in fiscal 2025 came from these product and service lines: Qbrexza $25.01 million (40%), Emrosi $14.74 million (23%), Accutane $12.88 million (20%), Foam franchise products (Amzeeq & Zilxi) $5.86 million (9%), Other / legacy product revenue $2.74 million (4%).

    Annual report (SEC XBRL) · Dec 2025

  • Coronado Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2017).

    SEC Form D · Apr 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2017

Products and services#

No products or services of Coronado Biosciences Inc. are on record.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Coronado Biosciences Inc.
InvestorKindAmountRoundRoleSource
Bobby W. SandagePersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2011)SEC Form 3
Dale RitterPersonnot statednot statedHeld Series C preferred stock (Form 3, 2011)SEC Form 3
Glenn L. CooperPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2011)SEC Form 3
Lindsay A. RosenwaldPersonnot statednot statedHeld Series A, B and C preferred stock, director (Form 3, 2011)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 344 investors.

Largest shareholders today

Institutions holding Fortress Biotech, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Coronado Biosciences Inc.
NameRoleNamed in
George K. AvgerinosExecutive officerApr 2017
Lindsay A. RosenwaldExecutive officerApr 2017
Lucy S. LuExecutive officerApr 2017
Bobby W. SandageExecutive officerJul 2011
Dale W. RitterExecutive officerJul 2011
Glenn L. CooperExecutive officerJul 2011
Elizabeth MooreExecutive officerJan 2011
Gary L. GemignaniExecutive officerJan 2011
Peggy M. WentworthExecutive officerJan 2011
Timothy M. HillmanExecutive officerJan 2011
Timothy M. HoferExecutive officerJan 2011
Elizabeth J. MooreExecutive officerJun 2010
Linda J. RogersExecutive officerJun 2010
Raymond J. TesiExecutive officerJun 2010
Stephen M. PilatzkeExecutive officerMay 2010
Linda RogersExecutive officerAug 2009
Peggy WentworthExecutive officerAug 2009
Stephen PilatzkeExecutive officerAug 2009
Dov K. KleinDirectorApr 2017
Eric K. RowinskyDirectorApr 2017
J. Jay LobellDirectorApr 2017
Jimmie S. Harvey, Jr.DirectorApr 2017
Lindsay A. RosenwaldDirectorApr 2017
Malcolm S. HoenleinDirectorApr 2017
Michael S. WeissDirectorApr 2017
Bobby W. SandageDirectorJul 2011
David J. BarrettDirectorJul 2011
Glenn L. CooperDirectorJul 2011
Jimmie Jay HarveyDirectorJul 2011
Michael W. RogersDirectorJul 2011
Jimmie M. HarveyDirectorJan 2011
Raymond J. TesiDirectorJun 2010
Bertrand LiangDirectorAug 2009
Jimmie HarveyDirectorAug 2009

About

Company.

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.